What Efelin-X PD Treats: Main Uses and Benefits

Efelin-X PD is a medication commonly used across conditions presenting with acute episodes of respiratory discomfort. This medication is considered relevant in the therapeutic area of respiratory support, which involves easing symptoms related to heightened physiological activity. This medication is applied across domains where additional symptomatic support is needed. This class of medication is central to managing recurrent or episodic manifestations of respiratory conditions.

Core Therapeutic Focus

This medicine is applied in addressing symptom clusters that may become intense or disruptive, including wheezing, chest tightness, and shortness of breath. It is generally relevant for managing symptoms that interfere with daily comfort, including those that create noticeable functional strain related to physical activity or sleep. Efelin-X PD is relevant in conditions characterized by periods of heightened symptoms, specifically chronic asthma.

The medication is commonly used when short-term symptomatic assistance is needed to address distressing manifestations. This provides support that contributes to easing the overall symptom load and offers symptomatic relief that helps patients cope more steadily with difficult episodes. It also helps improve day-to-day comfort during symptomatic periods and supports patients during episodes of heightened discomfort.

---

Quick Fact

Quick Fact: Supportive Relief for Symptoms of Breathing Difficulty.

Who Can and Cannot Use Efelin-X PD?

Eligibility for Efelin-X PD is determined by official regulatory labeling, which establishes populations for whom the medicine is contraindicated, restricted, or approved.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by patients with a known hypersensitivity to Terbutaline, Bromhexine, or any components. It is also prohibited for patients with pre-existing ischaemic heart disease and those with active gastric ulceration

or hypertrophic cardiomyopathy.

Age and Physiological Restrictions

Use is generally established for adults and adolescents (aged 12 and older). However, Efelin-X PD is not recommended for children younger than 6 years of age, as safety and effectiveness have not been established in this pediatric group. During pregnancy and lactation (breastfeeding), use is generally discouraged or permitted only with extreme caution, as components may be excreted in breast milk.

Condition-Based Limitations

Caution is required for several populations due to potential risks tied to the active components. This includes patients with uncontrolled diabetes mellitus, severe renal or hepatic impairment, thyrotoxicosis (hyperthyroidism), certain cardiovascular disorders (like arrhythmias or hypertension), and a history of seizure disorders.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Efelin-X PD, a fixed-dose combination of Terbutaline and Bromhexine, as classified by government regulatory authorities.

---

Pharmacodynamic and Contraindicated Interactions

Co-administration with Non-selective Beta-Adrenergic Receptor Blocking Agents (e.g., Propranolol) is generally not recommended as these agents may partially or totally inhibit the bronchodilator effect of Terbutaline. The combined use of Efelin-X PD with other Sympathomimetic Agents is also not recommended due to the potential for deleterious combined effects on the cardiovascular system.

Use with caution is documented for Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants due to the possibility of potentiating the vascular effects of Terbutaline. Similarly, co-administration with Xanthine Derivatives, Corticosteroids, or Diuretics may potentiate the hypokalemic effect (lowering of serum potassium) associated with the beta2-agonist component.

---

Pharmacokinetic and Exposure Considerations

The Bromhexine component may officially increase the concentration of certain concurrently administered antibiotics (such as Amoxycillin, Erythromycin, or Oxytetracycline) in bronchial secretions. Additionally, concomitant food intake has been shown to increase the plasma concentrations of Bromhexine. For patients with severe hepatic or renal impairment, the clearance of the Bromhexine component or its metabolites may be reduced, which is a relevant pharmacokinetic consideration.

How Efelin-X PD Works

The pharmacological action of Efelin-X PD is defined by a complementary dual mechanism targeting two distinct systems: the smooth muscle tone of the airways and the viscosity of respiratory secretions.

Modulating Bronchial Smooth Muscle Tone

This domain covers the action of the beta2-agonist component (Terbutaline), which engages beta2-adrenergic receptors on the bronchial smooth muscle. Activation of this receptor initiates the cAMP/PKA cascade, which reduces the intracellular calcium required for muscle contraction. This mechanism directly results in the relaxation and widening of constricted air passages, resulting in a reduction of airway resistance.

Altering the Rheology of Respiratory Secretions

This domain focuses on the mucolytic component (Bromhexine), which alters the physical properties of respiratory secretions by facilitating the depolymerization and hydrolysis of high-viscosity acidic mucopolysaccharide fibers. This chemical modification decreases the viscosity of secretions and promotes mucociliary clearance.

Synergistic Mechanistic Integration

The combination product integrates these two separate mechanisms—airway expansion and secretion thinning—to establish a coordinated physiological effect. By relaxing the airways, the diameter is widened; by thinning the secretions, the physical burden of the contents is diminished. This integration establishes a mechanical environment conducive to clearance processes, thereby enabling the movement of secretions through a pathway characterized by reduced constriction.

Efelin-X PD is an oral Fixed-Dose Combination (FDC) medicine, available as tablets and liquid forms (syrup or solution). Its proper use is defined by a standardized, thrice-daily schedule and specific administration requirements.

---

Official Dosing and Administration Schedule

Standard Dosage Regimens

Population	Dosing Schedule	Dosing Constraint (Terbutaline Component)
Adults (Standard)	Typically one unit (e.g., 2.5–5 mg Terbutaline component) three times daily (TID).	The maximum labeled daily dose should not exceed 15 mg per 24 hours.
Adolescents (12–15 years)	Typically 2.5 mg of the Terbutaline component three times daily.	The maximum labeled daily dose should not exceed 7.5 mg per 24 hours.
Children (<12 years)	Dosing with liquid forms is determined by body weight (weight-based calculation).	The dose should be calculated precisely using a calibrated measuring device.

---

Procedural Instructions

The medicine is administered orally and can generally be taken with or without food. The frequency is fixed, requiring administration at approximate 6 to 8-hour intervals to maintain the necessary therapeutic concentration.

Key Administration Rules:

• Hydration: Each dose should be taken with a full glass of water. This procedural step is specified to support the action of the Bromhexine component, which helps thin respiratory secretions.
• Liquid Forms: When using the syrup or oral solution, a calibrated measuring device must be used to ensure the exact dose is delivered.
• Renal Adjustment: The protocol for the Terbutaline component requires a 50% dose reduction for patients with significantly impaired kidney function (GFR less than 50 mL/min).
• Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped.

Research Evidence / Overview of Studies for Efelin-X PD

This overview describes the scope and structure of the available clinical research on Efelin-X PD, a fixed-dose combination product containing the bronchodilator Terbutaline and the mucolytic agent Bromhexine. The research summarized here outlines the types of studies conducted, the outcomes measured, and where scientific certainty remains low.

---

Evidence for Use in Chronic Obstructive Respiratory Diseases

Research for this use was studied for conditions involving periods of heightened symptoms such as chronic bronchitis. Studies primarily used Randomized Controlled Trials (RCTs) involving the components, and Systematic Reviews. These trials focused on measures of lung function and patient discomfort, such as changes in objective pulmonary function indexes (like FEV1), and examining the properties of respiratory secretions (like volume and viscosity).

The research describes patterns related to both components. Evidence concerning the specific fixed-dose combination appears to be supported by data derived from studies on the individual active agents. A limitation is that large-scale, contemporary RCTs specifically designed for this particular combination remain limited. Therefore, certainty remains low for comprehensive, long-term outcomes of the specific combination in this group.

---

Evidence for Use in Reversible Bronchial Airway Obstruction

This area focuses on research that examined the effects of the active components in patients with conditions characterized by fluctuating or episodic manifestations like chronic asthma. The foundation of the evidence for the component addressing airway constriction comes from Randomized Controlled Trials (RCTs). These trials monitored objective lung function tests and assessed patient-reported outcomes describing perceived discomfort.

Studies monitored whether the component targeting airway obstruction was associated with short-term changes in pulmonary function, consistent with how this class of medicine is studied. However, the data show patterns related to the mucolytic component's role in this specific group may be uncertain, as it is based on smaller, more heterogeneous studies. Findings were mixed regarding the role of secretion management in routine asthma care.

---

Research Gaps and Areas of Uncertainty

Scientific evidence highlights what is known — and what is still uncertain — regarding the combination product. Evidence quality varies across studies, with some older methodologies contributing to the data. This variance is one reason why the overall certainty remains low for key questions regarding the combination.

A key gap is that comparative evidence is lacking in modern, high-quality trials that assess the combination against other established treatments. Additionally, long-term effects are not fully established for the specific fixed-dose combination, and follow-up durations were limited in many studies.

Key Studies & References

1. The role of mucolytics in chronic respiratory diseases: A systematic review and meta-analysis.

Common questions about Efelin-X PD (FAQ)

Q: Can Efelin-X PD be taken with other prescription medications?

A: Official regulatory documents indicate that co-administration with certain other medicines is generally not recommended. For instance, combining it with non-selective beta-blockers may reduce its effectiveness, and using it with other sympathomimetic agents could increase the risk of cardiovascular effects. Caution is also advised when taken alongside certain antidepressants or diuretics. These warnings are based on the known risks associated with these drug classes.

Q: Does Efelin-X PD affect sleep patterns?

A: Official product information suggests that the medicine may have an indirect effect on sleep. This is because possible side effects include central nervous system effects such as nervousness, tremor, and headache, which may interfere with rest in some individuals. Some regulatory sources also list drowsiness as a possible side effect.

Q: What happens if Efelin-X PD is taken with alcohol?

A: Information on the direct interaction between this medication and alcohol is often described as unknown in regulatory documents. However, since Efelin-X PD may cause side effects like dizziness or drowsiness, using alcohol concurrently could potentially increase the risk or severity of these effects.

Q: Can Efelin-X PD be crushed, split, or chewed?

A: According to the official product information, tablets should generally be swallowed whole with water. Patients are typically cautioned not to crush, break, or chew the tablets. Maintaining the structural integrity of the tablet supports the intended function of the formulation, especially for medicines designed for prolonged or extended delivery.

Q: How does the extended-release component of Efelin-X PD change its effect compared to immediate-release?

A: The extended-release component is designed to maintain a necessary therapeutic concentration in the body over a longer period of time. This approach allows the medicine to be taken less frequently, such as three times daily, to provide a duration of effect that supports a fixed, less frequent administration schedule.

Q: Can Efelin-X PD be taken by people with kidney issues?

A: Official documentation advises that patients with pre-existing kidney conditions or significantly impaired kidney function should use this medicine with caution. If clearance of the medicine from the body is reduced, a change to the dose may be required to account for this possibility.

Q: Is Efelin-X PD a controlled substance?

A: The active components of Efelin-X PD are not typically classified as a controlled substance under regulatory bodies like the US Drug Enforcement Administration (DEA) Schedule.

Q: How quickly does Efelin-X PD usually start to work?

A: Regulatory information indicates that the onset of action for the bronchodilator component (Terbutaline) is usually within 30 to 45 minutes after taking the medicine orally. The action of the bronchodilator component is observed in this timeframe.

Q: Do you need a prescription to get Efelin-X PD?

A: This medicine is typically classified by regulatory authorities as a Prescription Drug (Schedule H or equivalent in some regions). This classification means it must be obtained with a prescription from a registered medical practitioner.

Q: Is it common to feel tired when first starting Efelin-X PD?

A: Generalized fatigue is not listed as a common adverse reaction in official documents. However, some regulatory sources list drowsiness and dizziness as possible side effects, which may make a person feel tired when treatment is initiated.

Q: Is there a list of common foods to avoid while taking Efelin-X PD?

A: Official regulatory documents do not provide a specific list of common foods to avoid while taking this medicine. They do note that food intake may slightly increase the plasma concentrations of the Bromhexine component, and official documents do not list any specific foods to avoid.

Q: Does Efelin-X PD interact with common over-the-counter pain relievers?

A: Official drug interaction listings include warnings about combined use with non-steroidal anti-inflammatory drugs (NSAIDs) such as Aspirin, especially regarding the potential effect on potassium levels. The label notes that all over-the-counter medicines, including pain relievers, are relevant to safety and interaction discussions.

Q: Is Efelin-X PD safe to use for older adults (seniors)?

A: Regulatory documents advise that use in elderly patients requires caution. This is generally due to an increased likelihood of reduced heart, kidney, or liver function in this population. For these reasons, the use of this medicine in older adults is generally under cautious supervision.

Q: Is Efelin-X PD known to cause changes in mood or anxiety levels?

A: Official documentation recognizes the potential for effects on the nervous system, with 'nervousness' listed as a common side effect of the bronchodilator component. While broader mood changes or anxiety are not explicitly listed, the effect on the nervous system is recognized.

Q: How long does Efelin-X PD stay in your system after stopping it?

A: The half-life of the Terbutaline component—the time it takes for half of the medicine to be cleared from the body—is approximately 5.7 hours. This measure indicates the period over which the body processes the medication.

Q: Has Efelin-X PD been studied in children or adolescents?

A: Regulatory documents indicate that the medicine's use is generally established for adolescents (12 and older) with specific dosing guidelines. The safety and effectiveness are officially stated as not established for children younger than six years of age.

Q: Is Efelin-X PD often used in combination with other treatments?

A: The official label contains warnings against using it with certain drug classes, such as other sympathomimetic agents. However, it also notes that Efelin-X PD may be used with other treatments, such as inhaled corticosteroids or certain diuretics, though the latter requires caution.

Q: Is Efelin-X PD the same drug as its generic version?

A: Efelin-X PD is a brand name for a fixed-dose combination. Generic versions of its active components—Terbutaline Sulfate and Bromhexine Hydrochloride—are available and contain the same active ingredients in the same strength and dosage form.

Q: Does Efelin-X PD have a 'black box' warning?

A: The active component Terbutaline has an FDA Black Box Warning. This warning restricts the oral use of the component Terbutaline for managing premature labor due to the risk of serious maternal adverse effects.

Q: What is meant by 'PD' in the name Efelin-X PD?

A: While the exact meaning of the letters 'PD' is not defined in the regulatory sources, the administration instructions for this product are characteristic of a 'Prolonged Duration' or 'Extended Duration' release formulation. This formulation ensures a sustained therapeutic effect.

Q: Can Efelin-X PD affect the results of lab tests?

A: Yes, regulatory information requires regular monitoring of both blood sugar (glucose) and serum potassium levels. This is because the medication can cause changes in these lab values, specifically potential hyperglycemia (high blood sugar) and hypokalemia (low potassium levels).

Q: What percentage of people report experiencing the most common side effects of Efelin-X PD?

A: The frequency of the most common side effects, such as tremor and palpitations, is officially classified as 'Very Common.' This classification means they are reported in 1 out of every 10 people, or more, who take the medicine.

Q: Is it necessary to take Efelin-X PD at the exact same time every day?

A: The procedural instructions require administration at approximate 6- to 8-hour intervals to maintain the necessary therapeutic concentration. While consistency is important, the use of 'approximate' suggests a small degree of flexibility is permitted.

Q: What happens if I accidentally take two doses of Efelin-X PD close together?

A: Regulatory guidance states that two doses should never be taken at once to make up for a missed dose. Taking too much of the medicine may lead to symptoms of overdose, such as tremors, an irregular heart rate, seizures, or changes in blood pressure.

Q: Are there any known interactions between Efelin-X PD and vitamin or herbal supplements?

A: The official label notes that the risk of hypokalemia (low potassium) is potentiated when taken with non-potassium-sparing diuretics. While specific supplements are not named, this interaction is relevant for potassium-containing supplements or those affecting electrolytes.

Q: Why is Efelin-X PD considered a Schedule X drug (or whatever standard classification)?

A: The medicine is classified as a Prescription Drug (Schedule H or equivalent) because its components are used to treat medical conditions requiring professional diagnosis and supervision. Furthermore, the product carries specific warnings and potential for adverse effects that necessitate medical oversight.

Q: Do I need to change my diet while taking Efelin-X PD?

A: Official regulatory documents do not mandate a specific change in diet. However, they do note that food intake can increase the plasma concentrations of the Bromhexine component. Additionally, adequate hydration is required with each dose to support the drug's action.

Q: Are there any restrictions on driving or operating machinery while on Efelin-X PD?

A: Regulatory warnings state that the medicine may cause dizziness or drowsiness in some individuals. Patients are cautioned that driving or operating machinery should only occur if they are certain they are alert and unimpaired after taking the medicine.

Q: Does Efelin-X PD cause sun sensitivity or skin issues?

A: The product label lists the potential for a skin rash as a possible side effect of the medicine, and also notes the rare possibility of hypersensitivity vasculitis. Direct sun sensitivity is not explicitly mentioned in the documents.

Q: Can I take Efelin-X PD if I have high blood pressure?

A: Official safety information advises that patients with pre-existing hypertension (high blood pressure) or certain cardiovascular disorders should use the medicine with caution. This is because the medicine can cause temporary changes in heart rate and blood pressure.

Q: What is the average duration of treatment with Efelin-X PD?

A: Regulatory guidance indicates that this medicine is generally prescribed for the short-term management of respiratory symptoms. The official guidance is that the medicine is typically used only for the duration specified by the prescribing doctor.

How to Store and Dispose of Efelin-X PD?

The official requirements for storing and disposing of Efelin-X PD are defined to maintain the product's stability and safety.

Storage Requirements

Storage Factor	Official Requirement
Temperature	Store at controlled room temperature, typically 25 C (77 F), with permitted excursions.
Protection	Keep the medicine in its original container, tightly closed, and protected from both moisture and light.
Handling	Protect the product from freezing. If it requires reconstitution, any unused portion must be refrigerated and discarded if not used within the specified in-use period (e.g., 24 hours).
Child Safety	Keep this and all medicines out of the sight and reach of children.

Disposal Requirements

To safely dispose of expired or unused Efelin-X PD, follow the procedures outlined on the product label or by your local municipality. Do not dispose of the medicine by flushing it down a toilet or pouring it down a drain unless specifically instructed to do so by a drug take-back program or regulatory document. This prevents environmental contamination and ensures safe waste management.